Announcements and Circulars

(REVISED) MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED OCTOBER 31, 2020

VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE ON RECOMMENDED BREAKTHROUGH THERAPY DESIGNATION FOR NEFECON FOR THE TREATMENT OF IGA NEPHROPATHY

VOLUNTARY ANNOUNCEMENT - BUSINESS UPDATE ON LICENSING PARTNER CALLIDITAS THERAPEUTICS REPORTING TOPLINE RESULTS FROM PIVOTAL PHASE 3 NEFIGARD TRIAL

MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 OCTOBER 2020

VOLUNTARY ANNOUNCEMENT - BUSINESS UPDATE OF FIRST PATIENT DOSED IN PHASE 2B REGISTRATION CLINICAL TRIAL OF TRODELVY TM (SACITUZUMAB GOVITECAN) FOR THE TREATMENT OF METASTATIC TRIPLE-NEGATIVE BREAST CANCER IN CHINA

VOLUNTARY ANNOUNCEMENT - BUSINESS UPDATE ON APPROVAL OF CLINICAL TRIAL APPLICATION BY CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION FOR PHASE 3 REGISTRATION TRIAL OF TRODELVY TM FOR METASTATIC BREAST CANCER IN CHINA

ANNOUCEMENT OF FULL EXERCISE OF THE OVER-ALLOTMENT OPTION, STABILIZING ACTIONS AND END OF STABILIZATION PERIOD

VOLUNTARY ANNOUNCEMENT - BUSINESS UPDATE ON THE COMPLETION OF PHASE 3 BRIDGING CLINICAL TRIAL OF XERAVA TM (ERAVACYCLINE) FOR THE TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS IN CHINA

ANNOUNCEMENT OF OFFER PRICE AND ALLOTMENT RESULTS